NO-donor phenols: A new class of products endowed with antioxidant and vasodilator properties

Journal of Medicinal Chemistry

Volumn 49, Issue 10, 2006, Pages 2886-2897

  Boschi, Donatella ^a   Tron, Gian Cesare ^b   Lazzarato, Loretta ^a   Chegaev, Konstantin ^a   Cena, Clara ^a   Di Stilo, Antonella ^a   Giorgis, Marta ^a   Bertinaria, Massimo ^a   Fruttero, Roberta ^a   Gasco, Alberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 BENZENESULFONYLFUROXAN 4 YLOXYMETHYL) 2,5,7,8 TETRAMETHYLCHROMAN 6 OL; 3 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL)PROPYL NITRATE; 3 (4 HYDROXY 3,5 DIMETHOXYPHENYL)PROPYL NITRATE; 3 (4 HYDROXYPHENYL)PROP 1,2 DIYL DINITRATE; 3 (4 HYDROXYPHENYL)PROPYL NITRATE; 3 [(4 HYDROXY 3,5 DI TERT BUTYL)PHENYL]PROP 1,2 DIYL DINITRATE; 3 [(4 HYDROXY 3,5 DIMETHOXY)PHENYL]PROP 1,2 DIYL DINITRATE; 3 [(6 HYDROXY 2,5,7,8 TETRAMETHYLCHROMAN 2 YL)METHOXY]PROPYL NITRATE; 4 [3 (3 BENZENESULFONYLFUROXAN 4 YLOXY)PROPYL] 2,6 DI TERT BUTYLPHENOL; 4 [3 (3 BENZENESULFONYLFUROXAN 4 YLOXY)PROPYL] 2,6 DIMETHOXYPHENOL; 4 [3 (3 BENZENESULFONYLFUROXAN 4 YLOXY)PROPYL]PHENOL; 4 [[N [(6 HYDROXY 2,5,7,8 TETRAMETHYLCHROMAN 2 YL)METHYL] N METHYLAMINO]METHYL]FUROXAN 3 CARBOXAMIDE; 4 [[N [3 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL)PROPYL] N METHYLAMINO]METHYL]FUROXAN 3 CARBOXAMIDE; ASCORBIC ACID; FERROUS ION; NITRIC OXIDE DONOR; PHENOL DERIVATIVE; PHENYLEPHRINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; AORTA STRIP; ARTICLE; ATHEROMA; CARDIOVASCULAR DISEASE; DRUG SYNTHESIS; LIPID PEROXIDATION; LIVER CELL; VASODILATATION;

ANIMALS; ANTIOXIDANTS; AORTA, THORACIC; LIPID METABOLISM; MALE; MICROSOMES, LIVER; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRATES; NITRIC OXIDE DONORS; OXADIAZOLES; OXIDATION-REDUCTION; PHENOLS; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VASODILATOR AGENTS;

EID: 33646744231     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0510530     Document Type: Article

References (33)

1. th ed.; Kasper, D. L., Braunwald, E., Fauci, A., Hauser, S., Longo, D., Jameson, J. L., Eds.; McGraw-Hill: New York, 2005; pp 1301-1304.
2. Eberhardt, M. K. Reactive Oxygen Metabolites; CRC: Boca Raton, FL, 2000;
3. (a) Reactive Oxygen Metabolites; pp 261-301;
4. (b) Reactive Oxygen Metabolites; pp 303-396.
5. Touyz, R. M. Reactive oxygen species, vascular oxidative stress and redox signaling in hypertension: What is the clinical significance? Hypertension 2004, 44, 248-252.
6. -/- mice. Biochem. Bioph. Res. Commun. 2005, 338, 1-6.
7. Keaney, J. F., Jr.; Vita, J. A. Atherosclerosis, oxidative stress and antioxidant protection in endothelium-derived relaxing factor actions. Prog. Cardiovasc. Dis. 1995, 38, 129-154.
8. (a) Shaw, C. A.; Megson, I. L.; Rossi, A. G. Apoptosis and atherosclerosis: The role of nitric oxide. Anti-Infl. Anti-Allergy Agent Med. Chem. 2006, 5, in press.
9. (b) Hare, J. M. Nitroso-redox balance in the cardiovascular system. N. Engl. J. Med. 2004, 351, 2112-2114.
10. (c) Ogita, H.; Liao, J. K. Endothelial function and oxidative stress. Endothelium 2004, 11, 123-132.
11. (d) Dillon, G. A.; Vita A. J. Nitric oxide and endothelial Dysfunction. In Contemporary Cardiology, vol.4: Nitric Oxide and the Cardiovascular System; Loscalzo, J., Vita, J. A., Eds.; Humana Press Inc.: Totowa, NJ, 2000; pp 207-226.
12. (a) Nicolaus B. J. R. Symbiotic approach to drug design. In Decision Making in Drug Research; Gross, F., Ed.; Raven Press: New York, 1983; pp 173-186.
13. (b) Christiaans, J. A. M.; Timmerman, H.; Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule. Eur. J. Pharm. Sci. 1996, 4, 1-22 and references therein.
14. (c) Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543 and references therein.
15. Cena, C.; Boschi, D.; Tron, G. C.; Chegaev, K.; Lazzarato, L.; Di Stilo, A.; Aragno, M.; Fruttero, R.; Gasco, A. Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. Bioorg. Med. Chem. Lett. 2004, 14, 5971-5974.
16. Luccarini, M.; Pedrielli, P.; Pedulli, G. F.; Cabiddu, S.; Fattuoni, C. Bond dissociation energies of O-H bonds in substituted phenols from equilibrium studies. J. Org. Chem. 1996, 61, 9259-9263.
17. (a) Civelli, M.; Giossi, M.; Caruso, P.; Razzetti, R.; Bergamaschi, M.; Bongrani, S.; Gasco, A. The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivatives CHF 2363. Br. J. Pharmacol 1996, 118, 923-928.
18. (b) Bohn, H.; Brendel, J.; Martorana, P. A.; Schönafinger, K. Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor. Br. J. Pharmacol. 1995, 114, 1605-1612.
19. Arya, P.; Alibhai, N.; Quin, H.; Burton, G. W. Design and synthesis of analogs of vitamin E: Antiproliferative activity against human breast adenocarcinoma cells. Bioorg. Med. Chem. Lett. 1998, 8, 2433-2438.
20. Dunstan, I.; Griffiths, J. V.; Harvey, S. A. Nitric Esters. Part I. Characterisation of the isomeric glycerol dinitrates. J. Chem. Soc. 1965, 1319-1324 and references therein reported.
21. Antolovich, M.; Prenzler, P. D.; Patsalides, E.; McDonald, S.; Robards, K. Methods for testing antioxidant activity. Analyst 2002, 127, 183-198.
22. (a) Sharpe, M. A.; Robb, S. J.; Clark, J. B. Nitric Oxide and Fenton/Haber-Weiss chemistry: Nitric oxide is a potent antioxidant at physiological concentrations. J. Neurochem. 2003, 87, 386-394.
23. (b) Rubbo, H.; Parthasarathy, S.; Barnes, S.; Kirk, M.; Kalyanaraman, B.; Freeman, B. A. Nitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives. Arch. Biochem. Biophys. 1995, 324, 15-25.
24. Ancerewicz, J.; Migliavacca, E.; Carrupt, P. A.; Testa, B.; Brée, F.; Zini, R.; Tillement J. P.; Labidalle, S.; Guyot, D.; Chauvet-Monges, A. M.; Crevat, A.; Le Ridant, A. Structure-property relationships of trimetazidine derivatives and model compounds as potential antioxidants. Free Radical Biol Med. 1998, 25, 113-120.
25. Sorba, G.; Ermondi, G.; Fruttero, R.; Galli, U.; Gasco, A. Unsymmetrically substituted furoxans. Part 16. Reaction of benzenesulfonyl substituted furoxans with ethanol and ethanethiol in basic medium. J. Heterocycl. Chem. 1996, 33, 327-334.
26. Di Stilo, A.; Visentin, S.; Cena, C.; Gasco, A. M.; Ermondi, G.; Gasco, A. New 1,4-dihydropyridine conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. J. Med. Chem. 1998, 41, 5393-5401.
27. Kline, R. H.; Parker, D. K. Alkylation of 2,6-di-tert-alkylphenols with alkanediols. US patent 4,260,832, October 29, 1979.
28. Parker, D. K. Process for production of 2,6-di-tert-alkenyl phenols. US Patent 4,366,331, December 28, 1982.
29. Marken, C. D.; Kristofferson, C. E.; Roland, M. M.; Manzara, A. P.; Barnes, M. W. A low hazard procedure for the laboratory preparation of polynitrate esters. Synthesis 1977, 484-485.
30. Schönafinger, K.; Bohn, H. Preparation of furazancarboxylic acid-derivative cardiovascular agents. DE Patent 4401150, April 1, 1994.
31. Pinard, E.; Alanine, A.; Bourson, A.; Buettelmann, B.; Gill, R.; Heitz, M.; Jaeschke, G.; Mutel, V.; Trube, G.; Wyler, R. Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl) -pi-peridin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist. Bioorg. Med. Chem. Lett. 2001, 11, 2173-2176.
32. Schmidt, K.; Mayer, B. Determination of NO with a Clark-type electrode. In Methods in Molecular Biology, vol. 100. Nitric oxide Protocols; Titheradge, M. A., Ed.; Humana Press Inc.: Totowa, NJ, 1998; pp 101-109.
33. Mastrocola, R.; Aragno, M.; Betetto, S.; Brignardello, E.; Catalano, M. G.; Danni, O.; Boccuzzi, G. Pro-oxidant effect of dehydroepiandrosterone in rats is mediated by PPAR activation. Life Sci. 2003, 73, 289-299.